licensing agreement

The companies will validate and commercialize the assay as a companion diagnostic to identify best responders to Morphotek's investigational ovarian cancer treatment.

The license is part of an ongoing cancer research collaboration between NovellusDx and Christiana Care's Gene Editing Institute.

The deal between GE, the Global Good Fund, and Access Bio is to manufacture and distribute malaria diagnostic technologies in low-resource nations.

The assay combines high-throughput drug screening of live, patient-derived tumor cells with DNA sequencing and data analysis to match patients with drug therapies.

Nova Satra said it will use the EpiSwitch technology to develop and commercialize non-invasive breast cancer testing across 13 territories in Asia.

The technology uses Thermo Fisher Scientific microarrays to measure transcript levels in order to diagnose rejection of solid organ transplants.

The contract includes a milestone of approval by the Chinese Food and Drug Agency within the next three years.

MDxHealth will use Ghent's methylation in situ hybridization technology to develop tests for urological cancers.